Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07342881 | Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function | PHASE1 | RECRUITING | 30 | — | — | Feb 20, 2026 | Jul 1, 2026 | Feb 27, 2026 | 2 | United States |
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Urine PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
Urine PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302
| Arm | Type | Description |
|---|---|---|
| Subjects with renal Impairment | EXPERIMENTAL | Subjects with renal impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug. |
| Subjects without renal impairment | EXPERIMENTAL | Subjects without renal impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug. |
| Name | Type | Description |
|---|---|---|
| Pevifoscorvir Sodium (ALG-000184) | DRUG | Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium |
Inclusion Criteria for All Subjects: 1. Male and Female between 18 and 75 years old 2. Body Mass Index (BMI) 17.5 to 40.0 kg/m\^2 and a total body weight \>50 kg (110 lb) 3. Female subjects must either be not of childbearing potential or if they are a woman of childbearing potential, they are only ...